Description: Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Home Page: actuatetherapeutics.com
1751 River Run
Fort Worth,
TX
76107
United States
Phone:
817 887 8455
Officers
| Name | Title |
|---|---|
| Mr. Daniel M. Schmitt | CEO, President & Director |
| Dr. Andrew P. Mazar Ph.D. | Co-Founder & COO |
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
| Mr. Paul J. Lytle CPA | Chief Financial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-08-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 11 |